新疗法精准识别并摧毁胰腺癌细胞

Core Viewpoint - A new CAR-NKT immunotherapy developed by the research team at UCLA shows promise in accurately identifying and destroying pancreatic cancer cells, even after metastasis to other organs [2][3] Group 1: Therapy Mechanism and Efficacy - The CAR-NKT cells are designed to target the protein "mesothelin" found on pancreatic cancer cells, enabling them to initiate multiple attack mechanisms against tumors [2] - In rigorous animal models for both primary pancreatic tumors and liver metastases, CAR-NKT cells demonstrated strong tumor-clearing capabilities, maintaining anti-cancer activity even in highly inflammatory tumor microenvironments [2] Group 2: Advantages Over Current Therapies - This new platform overcomes limitations of current cell therapies regarding time, process, and cost, as it allows for the use of donated blood stem cells for large-scale production without severe rejection reactions [3] - The targeted mesothelin is also highly expressed in breast, ovarian, and lung cancers, suggesting that the same cell preparation could potentially be used to treat multiple types of cancer [3]